Animal Study Suggests Similarities Between Addiction, ObesityAugust 21, 2008
Research Summary
A study examining the treatment potential of the medication vigabatrin indicates some similarities between addiction and obesity, Reuters reported Aug. 21.
The study using rats found that the drug, also known as GVG and now being tested for use to treat addiction in humans, led to a weight loss of up to 19 percent in rodent subjects bred to be obese. A research team at the federal government's Brookhaven National Laboratory reported that steady weight loss while the rats were receiving vigabatrin was followed by steady weight gain when they were off the medication.
"It was also dose-dependent," said researcher Amy DeMarco. "Rats given higher doses would lose more weight."
The researchers said the medication appears to work on the brain's dopamine reward system, which governs both addictive and overeating behaviors. Vigabatrin is presently being tested for use in the treatment of cocaine and methamphetamine addiction. The company conducting these Phase II trials, Catalyst Pharmaceutical Partners, Inc. of Coral Gables, Fla., also plans to test the medication for alcohol dependence and binge eating disorder.
Study results were published in the journal Synapse.

This article
summarizes an external report or press release on research published in a scientific journal. When available, links to the sources are provided above.
COMMENTS ON THIS ARTICLE: